These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8284832)

  • 1. Nalmefene in the treatment of interstitial cystitis.
    Stone NN
    Urol Clin North Am; 1994 Feb; 21(1):101-6. PubMed ID: 8284832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
    Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder.
    Glover H
    Isr J Psychiatry Relat Sci; 1993; 30(4):255-63. PubMed ID: 8163362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical observation of the effect of nalmefene in treatment of septic shock].
    Wang HL; Yu KJ; Liu HT
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Jun; 22(6):351-3. PubMed ID: 20594468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
    Dodman NH; Shuster L; Court MH; Patel J
    J Am Vet Med Assoc; 1988 Jun; 192(11):1585-6. PubMed ID: 3410777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC; Kleppner SR; McDonough J; Azar MR; Patel R
    Int J Pharm; 2004 Sep; 283(1-2):35-44. PubMed ID: 15363499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of nalmefene on side effects due to intrathecal morphine at cesarean section.
    Pellegrini JE; Bailey SL; Graves J; Paice JA; Shott S; Faut-Callahan M
    AANA J; 2001 Jun; 69(3):199-205. PubMed ID: 11759562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone effects on short-term and long-term smoking cessation.
    Covey LS; Glassman AH; Stetner F
    J Addict Dis; 1999; 18(1):31-40. PubMed ID: 10234561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs.
    Dodman NH; Shuster L; White SD; Court MH; Parker D; Dixon R
    J Am Vet Med Assoc; 1988 Oct; 193(7):815-9. PubMed ID: 3192459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid antagonists in the treatment of impulse-control disorders.
    Kim SW
    J Clin Psychiatry; 1998 Apr; 59(4):159-64. PubMed ID: 9590665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
    Kaplan JL; Marx JA
    Ann Emerg Med; 1993 Feb; 22(2):187-90. PubMed ID: 8427429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial watch: Nalmefene reduces alcohol use in phase III trial.
    Nat Rev Drug Discov; 2011 Aug; 10(8):566. PubMed ID: 21804585
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective effect of nalmefene and naloxone on the ischemically damaged small bowel.
    Lopez J; Naujokat P; Xavier R; Walters W; Toledo-Pereyra LH
    Transplant Proc; 1991 Oct; 23(5):2448-9. PubMed ID: 1926426
    [No Abstract]   [Full Text] [Related]  

  • 20. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J; Brewer C; Steele T
    Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.